Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion

Elias J. Anaissie*, Gloria N. Mattiuzzi, Carole B. Miller, Gary A. Noskin, Marc J. Gurwith, Richard D. Mamelok, Larry A. Pietrelli

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Amphotericin B colloidal dispersion (ABCD) is a new formulation of conventional amphotericin B designed to minimize drug distribution in the kidney and reduce nephrotoxicity. We studied the safety and efficacy of ABCD in 133 renally compromised patients with invasive fungal infections. Patients had either nephrotoxicity from amphotericin B or preexisting renal disease. Intravenous treatment with ABCD (4 mg/kg of body weight daily) was administered for up to 6 weeks. Evaluations included clinical response to treatment and adverse events, with emphasis on changes in serum creatinine levels. ABCD did not appear to have an adverse effect on renal function: mean serum creatinine level tended to decrease slightly with days on therapy, and increases were not dose related. Complete or partial response to treatment was reported for 50% of the 133 intent-to-treat patients and 67% of the 58 evaluable patients.

Original languageEnglish (US)
Pages (from-to)606-611
Number of pages6
JournalAntimicrobial agents and chemotherapy
Volume42
Issue number3
DOIs
StatePublished - Mar 1998

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion'. Together they form a unique fingerprint.

Cite this